DBD vs PODD · P/E 28, rev $3.75B vs P/E 34, rev $2.07B
Diebold Nixdorf, Incorporated (DBD) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
DBD currently screens at market cap $2.82B and trailing P/E 28.1. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the DBD and PODD stock pages for the full models.
Not investment advice.